# Clinical Trials Data ERBB2 - Document 36

# HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598

## Clinical Trial: https://clinicaltrials.gov/study/NCT00896909

"eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n\* Diagnosis of non-small cell lung cancer meeting \u2265 1 of the following criteria:\n\n \* Recurrent disease\n \* Stage IIIB with pleural or pericardial effusion\n \* Stage IV disease\n\* Treated on protocol ECOG-2598\n\nPATIENT CHARACTERISTICS:\n\n\* Not specified\n\nPRIOR CONCURRENT THERAPY:\n\n\* See Disease Characteristics",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a ERBB2 gene mutation be eligible for the clinical trial?

Answer:  
To determine if a patient with an ERBB2 gene mutation is eligible for this clinical trial, we need to focus on the eligibility criteria provided:  
  
1. \*\*Disease Characteristics:\*\*  
 - The patient must have a diagnosis of non-small cell lung cancer (NSCLC) that meets at least one of the following conditions:  
 - Recurrent disease  
 - Stage IIIB with pleural or pericardial effusion  
 - Stage IV disease  
 - Additionally, the patient must have been treated on protocol ECOG-2598.  
  
2. \*\*Patient Characteristics:\*\* There are no specific genetic mutations mentioned in the eligibility criteria.  
  
3. \*\*Sex and Age:\*\*  
 - The trial accepts all sexes.  
 - The minimum age is 18 years, with the trial open to adults and older adults.  
  
Given this information, the presence of an ERBB2 gene mutation is not specifically mentioned as a criterion for inclusion or exclusion. Therefore, a patient with an ERBB2 gene mutation would not automatically be excluded based on the mutation alone, as long as they meet the outlined disease characteristics (NSCLC with the specified disease stages or recurrence and ECOG-2598 treatment) and other general criteria.   
  
If you have more details on such protocol ECOG-2598 and its treatment, that could influence the eligibility assessment further. Otherwise, based on the provided criteria, the presence of an ERBB2 mutation does not independently determine eligibility.